The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study

The life expectancy of patients with psychotic disorders is significantly shorter than that of the general population; antipsychotic-induced metabolic disorders play a significant role in reducing life expectancy. Both metabolic syndrome (MetS) and schizophrenia are multifactorial conditions. One area where the two conditions overlap is oxidative stress, which is present in both diseases. The glutathione-S-transferase (GST) system is a major line of defense against exogenous toxicants and oxidative damage to cells. The aim of our study was to perform an association analysis of gene polymorphisms with metabolic disorders in patients with schizophrenia treated with antipsychotic therapy. <b>Methods</b>: A total of 639 white patients with schizophrenia (ICD-10) from Siberia (Russia) were included in the study. Genotyping was carried out using real-time polymerase chain reaction for two single-nucleotide polymorphisms (SNPs) in the <i>GSTP1</i> (rs614080 and rs1695) and one SNP in the <i>GSTO1</i> (rs49252). <b>Results</b>: We found that rs1695*GG genotype of <i>GSTP1</i> is a risk factor for the development of overweight (OR 2.36; 95% CI: 1.3-4.29; <i>p</i> = 0.0054). In the subgroup of patients receiving first-generation antipsychotics as basic therapy, the risk of overweight was associated with carriage of the rs1695*GG (OR 5.43; 95% CI: 2.24-13.16; <i>p</i> < 0.001) genotype of <i>GSTP1</i> in a recessive model of inheritance. In contrast, an association of rs1695*G GSTP1 with obesity (OR: 0.42; 95% CI: 0.20-0.87; <i>p</i> = 0.018) was shown in the dominant model of inheritance in patients receiving second-generation antipsychotics. <b>Conclusions</b>: The pilot results obtained confirm the hypothesis of a violation of the antioxidant status, in particular the involvement of <i>GSTP1,</i> in the development of antipsychotic-induced metabolic disorders in schizophrenia. Further studies with larger samples and different ethnic groups are needed to confirm the obtained results.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2025-06-21
DOI
https://doi.org/10.3390/ph18070941
Primary Topic
Glutathione Transferases and Polymorphisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study

Natalya M. Vyalova, Elena G. Kornetova, Nikolay A. Bokhan, Irina A. Mednova et al.
Pharmaceuticals
Glutathione Transferases and Polymorphisms
article

The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study

Natalya M. Vyalova, Elena G. Kornetova, Nikolay A. Bokhan, Irina A. Mednova, Ekaterina V. Mikhalitskaya, V. V. Tiguntsev, Svetlana А. Ivanova, Diana Z. Paderina, D. A. Petkun
article en

Abstract

The life expectancy of patients with psychotic disorders is significantly shorter than that of the general population; antipsychotic-induced metabolic disorders play a significant role in reducing life expectancy. Both metabolic syndrome (MetS) and schizophrenia are multifactorial conditions. One area where the two conditions overlap is oxidative stress, which is present in both diseases. The glutathione-S-transferase (GST) system is a major line of defense against exogenous toxicants and oxidative damage to cells. The aim of our study was to perform an association analysis of gene polymorphisms with metabolic disorders in patients with schizophrenia treated with antipsychotic therapy. <b>Methods</b>: A total of 639 white patients with schizophrenia (ICD-10) from Siberia (Russia) were included in the study. Genotyping was carried out using real-time polymerase chain reaction for two single-nucleotide polymorphisms (SNPs) in the <i>GSTP1</i> (rs614080 and rs1695) and one SNP in the <i>GSTO1</i> (rs49252). <b>Results</b>: We found that rs1695*GG genotype of <i>GSTP1</i> is a risk factor for the development of overweight (OR 2.36; 95% CI: 1.3-4.29; <i>p</i> = 0.0054). In the subgroup of patients receiving first-generation antipsychotics as basic therapy, the risk of overweight was associated with carriage of the rs1695*GG (OR 5.43; 95% CI: 2.24-13.16; <i>p</i> < 0.001) genotype of <i>GSTP1</i> in a recessive model of inheritance. In contrast, an association of rs1695*G GSTP1 with obesity (OR: 0.42; 95% CI: 0.20-0.87; <i>p</i> = 0.018) was shown in the dominant model of inheritance in patients receiving second-generation antipsychotics. <b>Conclusions</b>: The pilot results obtained confirm the hypothesis of a violation of the antioxidant status, in particular the involvement of <i>GSTP1,</i> in the development of antipsychotic-induced metabolic disorders in schizophrenia. Further studies with larger samples and different ethnic groups are needed to confirm the obtained results.

PharmaceuticalsVol. 18(7)
Russian Academy of Sciences (RU), Siberian State Medical University (RU), Tomsk National Research Medical Center (RU)
Russian Science Foundation
Openalex Percentile: Top 87%
Glutathione Transferases and Polymorphisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.